Vincent M. Desiato, DO¹; Nicholas Purdy, DO¹; Kenneth W. Altman, MD, PhD^{1,2}; Kevin P. Stavrides, MD¹; Thorsen W. Haugen, MD¹; Phillip K. Pellitteri, DO¹; Priscilla F.A. Pichardo, DO¹; Ryan N. Hellums, DO¹; Season Whitenight, PA-C¹ Geisinger Medical Center, Danville, PA

Introduction


Background •Access to specialty-level care is challenging in rural health systems and compounded by the COVID-19 pandemic.	Table 1. Characteristics of Cohort	
	Total cohort, N (%)	651 (100%)
	Mean age in years (SD)	65.7 (13.25)
 Head and neck cancer care considerations Access to care: impacts stage at diagnosis(1,2) Stage at diagnosis: strongest predictor of mortality(3) Delayed referral: Three-fold increased risk of mortality(4) Delayed treatment initiation: Increased risk of recurrence(5) Decreased overall survival(5) 	Demographics	N (%)
	Gender	
	Female	156 (24.0%)
	Male	495 (76.0%)
	Smoking history	449 (69.0%)
	Smokeless tobacco history	69 (10.7%)
	Alcohol history	291 (44.7%)
 Potential impact of COVID-19 pandemic Reduced outpatient clinical capacity Delay in presentation, reluctance to seek care due to risk of COVID-19 exposure Implementation of telemedicine 	Status of diagnosis at referral	N (%)
	Diagnosed	254 (39.1%)
	Undiagnosed	397 (60.9%)
	Distance from provider	Miles
Primary objective: •Analyze factors that influence access to care and examine potential group differences between those diagnosed and undiagnosed.	Mean (SD)	44.3 (32.55)
	Median (IQR)	41.6 (14.2, 63.9)
	Stage of disease	N (%)
	Early Stage (I/II)	189 (37.7%)
Methods and materials Design/Setting: Retrospective review of head and neck cancer tumor board data at a rural tertiary care center	Stage I	121 (24.2%)
	Stage II	68 (13.6%)
	Advanced Stage (III/IV)	312 (62.3%)
	Stage III	119 (23.8%)
nclusion criteria:	Stage IV	193 (38.5%)

•New primary head and neck cancer cases •Date range: 1/1/20 to 12/31/2022 Exclusion criteria: •Primary thyroid malignancy, lymphoma Absent/incomplete data

Primary outcome:

•Time from referral to tumor board presentation and treatment start date

Statistical Analysis Descriptive statistics



Factors impacting rural access for head and neck cancer during COVID-19

Treatment Start



Discussion

 Access to care has been associated with factors that impact prognosis and outcomes for head and neck cancer

•External (rural geography, COVID-19) and internal aspects pose potential barriers to access

•This study investigated access to care for patients with head and neck cancer in a rural healthcare system serving over 3 million people, and found that distance to provider did not significantly impact access to care

•Time to tumor board was significantly increased if undiagnosed at time of referral; however, time to establish diagnoses prior to referral is unknown

•Those with advanced stage disease had shorter time to tumor board, suggesting access to care may be expedited in certain cases

•Timeline and critical time points were established based on status of diagnosis at referral, defining opportunities to optimize care

•Findings reported by this study may serve as standard for comparison and be utilized to prospectively advance patient care.

- 1. Adrien J, Bertolus C, Gambotti L, Mallet A, Baujat B. Why are head and neck squamous cell carcinoma diagnosed so late? Influence of health care disparities and socio-economic factors. Oral Oncol. 2014 Feb;50(2):90-7. doi: 10.1016/j.oraloncology.2013.10.016. Epub 2013 Nov 20. PMID: 24268629.
- 2. Farquhar DR, Masood MM, Lenze NR, et al. Travel time to provider is associated with advanced stage at diagnosis among low income head and neck squamous cell carcinoma patients in North Carolina. Oral Oncol. 2019;89:115-120. doi:10.1016/j.oraloncology.2018.12.029
- 3. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005 May 1;114(5):806-16. doi: 10.1002/ijc.20740.
- 4. Seoane J, Takkouche B, Varela-Centelles P, Tomás I, Seoane-Romero JM. Impact of delay in diagnosis on survival to head and neck carcinomas: a systematic review with meta-analysis. Clin Otolaryngol. 2012
- 5. Coca-Pelaz A, Takes RP, Hutcheson K, Saba NF, Haigentz M Jr, Bradford CR, de Bree R, Strojan P, Lund VJ, Mendenhall WM, Nixon IJ, Quer M, Rinaldo A, Ferlito A. Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome. Adv Ther. 2018 Feb;35(2):153-160.

Geisinger Commonwealth School of Medicine